Bank of America just raised its EUR/USD forecast
On Monday, Stifel analysts reiterated their Buy rating and $80.00 price target for Jasper Therapeutics (NASDAQ:JSPR), currently trading at $6.17, following a company dinner with key management members after a presentation at the AAAAI meeting. According to InvestingPro data, analyst targets range from $38 to $80, reflecting significant upside potential from current levels. Jasper’s CEO Ronald Martell, CFO Herb Cross, and IR Alex Gray were present to discuss the company’s progress and future plans, particularly regarding their drug candidate, briquilimab.
The management team outlined a clear strategy, indicating that data expected to be released mid-year will provide a deeper insight into briquilimab’s safety and efficacy at higher doses. With a market capitalization of $93.91M and a strong current ratio of 4.98, InvestingPro data shows the company holds more cash than debt, though it’s quickly burning through its reserves. Stifel’s analysts believe the initial BEACON study data have shown that briquilimab is effective and could potentially match or surpass the performance of a similar drug, barzolvolimab, which is covered by Stifel’s Alex Thompson.
The analysts noted that while briquilimab’s high maximum concentration (Cmax) and short area under the curve (AUC) are indicators of its efficacy, the investment community is keenly anticipating evidence that this could lead to lower accumulation of on-target toxicity over time. According to Stifel, Jasper Therapeutics’ stock price reflects a high level of skepticism, valuing the company nearly at its cash level.
Despite this skepticism, Stifel’s analysts maintain a positive outlook, suggesting that even if briquilimab does not demonstrate a significant differentiation, a KIT-monoclonal antibody like briquilimab should still hold value within the broader context of mast cell-driven indications. The firm’s stance remains that the potential for differentiation is high, and they expect this to become more apparent with the upcoming mid-year data. With earnings due in just 2 days, InvestingPro subscribers can access the complete financial health analysis and 13 additional ProTips to make informed investment decisions.
In other recent news, Jasper Therapeutics reported a net loss of $1.62 per share for the fourth quarter of 2024, while maintaining a strong cash position with $72 million in cash and equivalents. Cantor Fitzgerald reaffirmed its Overweight rating on Jasper Therapeutics, reflecting a positive outlook based on the company’s financial health and revised earnings projections. RBC Capital Markets adjusted its price target for Jasper Therapeutics to $48, down from $68, following initial data from the BEACON study, yet retained an Outperform rating due to potential future milestones. BTIG also lowered its price target to $64 from $90 but maintained a Buy rating, citing promising results from a 240mg dose of briquilimab in the BEACON study. JMP Securities kept its Market Outperform rating and $70 price target, expressing cautious optimism about briquilimab’s market potential. Jasper Therapeutics is set to present data from its briquilimab study at the upcoming American Academy of Dermatology Annual Meeting, which could provide further insights into the drug’s efficacy. These developments indicate ongoing evaluations of briquilimab’s role in treating chronic spontaneous urticaria, with several analyst firms maintaining confidence in Jasper Therapeutics’ future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.